However, therapeutically approved and selective inhibitors for better gastric safety and breast cancer showed adverse cardiovascular side effects, leading to provoke researchers to identify and evaluate an alternate with potential COX-2 inhibitory activity [8]. This evidence concerns the gene PTGS2 and breast carcinoma.